Table 1.
Baseline characteristics of subjects in genetic sub-study of CORONA
| Characteristics of patients | n = 3,320 |
|---|---|
| Age (years) | 72.3 ± 6.9 |
| Males n (%) | 2530 (76.2) |
| Left ventricular ejection fraction (% ± SD) | 31 ± 6.3 |
| NYHA class n (%) | |
| II | 1251 (37.7) |
| III | 2035 (61.3) |
| IV | 34 (1.0) |
| History of n (%) | |
| Angina Pectoris | 2463 (74.2) |
| Aortic Aneurysm | 84 (2.5) |
| Aortic Aneurysm Surgery Performed | 47 (1.4) |
| Atrial Fibrillation/Flutter | 1318 (39.7) |
| Diabetes Mellitus | 933 (28.1) |
| Hypertension | 2173 (65.5) |
| Implantable cardioverter-defibrillator | 79 (2.4) |
| Implanted pacemaker | 349 (10.5) |
| Intermitted claudication | 392 (11.8) |
| Myocardial infarction | 1986 (59.8) |
| Coronary Artery Bypass Surgery | 537 (16.2) |
| Percutaneous Coronary Intervention | 358 (10.8) |
| CABG or PCI | 823 (24.8) |
| Stroke | 386 (11.6) |
| Smoking status n (%) | |
| Non Smoker | 1521 (45.8) |
| (Ex-)smoker | 1797 (54.1) |
| Heart Failure Medication at baseline n (%) | |
| Loop diuretic | 2421 (72.9) |
| Thiazide diuretic | 776 (23.4) |
| Loop or Thiazide | 2879 (86.7) |
| Beta-Blocker | 2542 (76.6) |
| ACE inhibitor | 2696 (81.2) |
| AT1-receptor blocker | 428 (12.9) |
| ACE inhibitor or AT1-receptor blocker | 3063 (92.3) |
| Aldosterone antagonist | 1284 (38.7) |
| Digitalis | 1072 (32.3) |
| Anti-platelet or Anti-coagulant | 3020 (91.0) |
| Blood pressure (mmHg) | |
| Systolic | 130.5 ± 16.1 |
| Diastolic | 77.0 ± 8.6 |
| Heart rate (beats/min) | 71.2 ± 10.9 |
| BMI (kg/m2) | 27.5 ± 4.4 |
| Serum creatinine (umol/L) | 112.8 ± 26.5 |
| eGFR (ml/min/1.73 m/m2BSA) | 58.5 ± 14.0 |
| hs-CRP (mg/L) | 3.3 (0.02-230) |
| NT-proBNP (pmol/L) | 151 (1–3868) |
| Lipids | |
| Total cholesterol (mmol/L) | 5.41 ± 1.07 |
| LDL-cholesterol (mmol/L) | 3.60 ± 0.94 |
| HDL-cholesterol (mmol/L) | 1.19 (0.47-3.55) |
| Apo-A1 (g/L) | 1.51 ± 0.27 |
| Apo-B (g/L) | 1.28 ± 0.30 |
| Apo-B/Apo-A (mean) | 0.87 ± 0.24 |
| Triglycerides (mmol/L) | 1.68 (0.41-14.43) |
Abbreviations: NYHA New York Heart Association, CABG Coronary Artery Bypass Graft, PCI Percutaneous Coronary Intervention, ACE Acetylcholinesterase, AT1 Angiotensin-1, BMI body mass index, eGFR estimated Glomerular Filtration Rate, hs-CRP high sensitive C-reactive protein, NT-proBNP N-terminal pro B-type natriuretic peptide, LDL low-density lipoprotein, HDL high-density lipoprotein, Apo apolipoprotein. Variables are expressed as mean (SD) when normally distributed and as median (min-max) when non-normally distributed.